Management of scleroderma renal crisis

Area of Science:

• Nephrology
• Rheumatology
• Internal Medicine

Background:

• Scleroderma renal crisis (SRC) is a critical manifestation of systemic sclerosis (SSc).
• SRC typically presents as acute severe hypertension and acute kidney injury.
• Understanding SRC as a systemic syndrome beyond kidney involvement is essential.

Purpose of the Study:

• To review risk factors for SRC in systemic sclerosis (SSc) patients.
• To highlight the importance of early identification and treatment of SRC.
• To inform clinicians on current and emerging therapeutic strategies for SRC.

Main Methods:

• Literature review of Scleroderma Renal Crisis (SRC) and Systemic Sclerosis (SSc).
• Analysis of current treatment modalities, including angiotensin-converting enzyme inhibitors (ACE-I).
• Exploration of novel therapeutic targets and combinations for refractory SRC.

Main Results:

• Angiotensin-converting enzyme inhibitors (ACE-I) have significantly improved outcomes in SRC.
• SRC remains a leading cause of mortality in SSc patients.
• Research is ongoing into combination therapies (e.g., ACE-I with endothelin receptor blockers, complement inhibitors) for ACE-I refractory SRC.

Conclusions:

• Early diagnosis and prompt initiation of ACE-I are life-saving for SRC patients.
• Renal transplantation should be considered for select patients with end-stage renal disease due to SRC.
• Prophylactic use of ACE-I in high-risk patients is not recommended.